BioVie (BIVI)
(Delayed Data from NSDQ)
$0.41 USD
+0.01 (2.53%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $0.41 0.00 (-0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIVI 0.41 +0.01(2.53%)
Will BIVI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BIVI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIVI
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now
BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
BIVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data
Other News for BIVI
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024
BioVie unveils protocol design of SUNRISE-PD Phase 2 trial of NE3107
BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
BioVie presents protocol design for upcoming Phase 2 trial of bezisterim